[Therapeutic strategies in Parkinson's disease].
Shoulson
I
I
Department of Neurology, University of Rochester Medical Center, N.Y.
D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015259:Dopamine Agents / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D009410:Nerve Degeneration / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D010479:Pergolide / Q000494:pharmacology / Q000627:therapeutic use; D011954:Receptors, Dopamine / Q000187:drug effects; D012642:Selegiline / Q000627:therapeutic use; D014810:Vitamin E / Q000627:therapeutic use
D000975:Antioxidants; D000978:Antiparkinson Agents; D015259:Dopamine Agents; D011954:Receptors, Dopamine; D014810:Vitamin E; D010479:Pergolide; D012642:Selegiline; D007980:Levodopa
Estrategias terapéuticas en la enfermedad de Parkinson.